logo
Plus   Neg
Share
Email
Comment

GTXI Q2 Loss Widens

GTX Inc. (GTXI) reported that its second-quarter net loss was $12.8 million or $0.20 per share, compared to a net loss of $10.4 million or $0.17 per share for the same period in 2012. Analysts polled by Thomson Reuters expected the company to report a loss of $0.22 per share for the quarter. Analysts' estimates typically exclude special items.

The company's net loss for the second quarter of 2012 was reduced by net income from discontinued operations of $848,000 related to sales of the commercial product FARESTONĀ®, the rights for which the Company sold in the third quarter of 2012.

Research and development expenses for the quarter were $10.1 million compared to $9.2 million for the same period of 2012. General and administrative expenses for the quarter ended were $2.7 million compared to $2.4 million for the same period of 2012.

GTx said it is evaluating enobosarm (GTx-024) 3 mg, an oral selective androgen receptor modulator, for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer in two pivotal Phase 3 clinical trials. The last patients completed these clinical trials during May 2013.
Vital status (survival) of patients participating in the studies will continue to be periodically monitored in accordance with the clinical trial protocols.

The company anticipates providing the topline results for both studies later this quarter which will include the coprimary endpoints, safety assessments, and an update on survival.

GTx noted that it continues to enroll the Phase 2, open label clinical trial evaluating enobosarm 9 mg for the treatment of androgen receptor positive and estrogen receptor positive metastatic breast cancer in women who have previously responded to hormonal therapy for the treatment of their advanced breast cancer, which was initiated in the second quarter of 2013. Additionally, GTx continues the enrollment of the Phase 2 clinical trial evaluating Capesaris (GTx-758), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Citigroup Inc.'s co-head of mergers and acquisitions, Peter Tague, is leaving the company, according to media reports, citing people familiar with the matter. Tague has been co-head of Global M&A business at Citigroup since March 2012, alongside Cary Kochman and Mark Shafir. It was not immediately clear what Tague intends to do after he leaves Citigroup. Loblaw Companies Ltd. Thursday reported a drop in its profit and revenues for the fourth quarter, as the Canadian supermarket chain continues to be impacted by the industry-wide price bread price-fixing scandal. In December, Loblaw confirmed that it had participated in an industry-wide arrangement... Starting this summer, Be Our Guest Restaurant in Magic Kingdom plans to offer a new French-inspired prix fixe dinner menu for its customers. According to reports, the new three-course dinner menu will be unique to the guests and will make them feel royal. The new menu will start on July 27 and...
comments powered by Disqus
Follow RTT